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A B S T R A C T
Studies revealed that the use of renin-angiotensin-aldosterone system antagonism is not associated with a sta-
tistically significant reduction in the risk of cardiovascular events in patients with chronic kidney disease (CKD)
compared with that in the general population. We tested the hypothesis that indoxyl sulfate (IS) can interfere
with the protective effect of valsartan-mediated on endothelial function in vitro and neovascularization in mice
underwent subtotal nephrectomy. In human aortic endothelial cells, we first demonstrated that IS impaired the
valsartan-mediated phosphorylation of eNOSThr495, nitric oxide production and tube formation via NADPH
oxidase (NOX) and protein kinase C (PKC) phosphorylation, but this effect was suppressed by cotreatment with
apocynin and calphostin C. In vivo, IS attenuated valsartan-induced angiogenesis in Matrigel plugs in mice.
Moreover, in subtotal nephrectomy mice who underwent hindlimb ischemic surgery, valsartan significantly
increased the mobilization of endothelial progenitor cells in circulation as well as the reperfusion of blood flow
and density of CD31+ capillaries in ischemic limbs. However, IS attenuated the protective effect of valsartan-
induced neovascularization and increased the expression of p-PKCαSer657 and p-eNOSThr497 in ischemic limbs.
Cotreatment of apocynin and calphostin C reversed the IS impaired-neovascularization and decreased the ex-
pression of p-PKCαSer657 and p-eNOSThr497 in ischemic limbs. Our study suggests that the NOX/PKC/eNOS
signaling pathway plays a pivotal role in the IS-mediated inhibition of valsartan-conferred beneficial effects on
endothelial function in vitro and neovascularization in subtotal nephrectomy mice. We proposed a novel cau-
sative role for IS in cardiovascular complications in CKD patients.
1. Introduction
Several studies have demonstrated that a substantially high risk of
cardiovascular (CV) events exists in CKD patients [1,2]. Cardiovascular
disease (CVD) is the leading cause of death in patients with CKD,
especially for those on long-term dialysis [3]. Risk factors for CVD
among CKD patients are not fully understood but probably include both
conventional and uremia-associated risk factors. Uremic toxins are re-
tained in the circulation of patients with CKD and are classified into free
water-soluble low-molecular weight solutes, middle molecules, and
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protein-bound solutes, including indoxyl sulfate (IS), indole-3-acetic
acid, p-cresyl sulfate, hippuric acid, and homocysteine [4]. Among
these protein-bound uremic toxins, IS is the most representative, as a
growing number of publications support its biological effects. A number
of mechanisms have been reported regarding the detrimental effects of
IS accumulation, such as increased reactive oxygen species (ROS) pro-
duction, upregulation of nicotinamide adenine dinucleotide phosphate
oxidase (NADPH oxidase), and reduced nitric oxide (NO) bioavailability
[5–7]. However, conventional dialysis cannot remove IS, as 90% of it is
bound to albumin, and IS–albumin complexes are too large to pass
through the pores in dialysis membranes. These factors may be underlie
why high serum IS levels are associated with a high number of CV
events in CKD, even after dialysis [8].
Renin-angiotensin-aldosterone system (RAAS) blockades, including
the angiotensin converting enzyme inhibitor (ACE inhibitor) and an-
giotensin II receptor blocker (ARB), represent the premiere medical
therapeutic strategy for combating CKD progression, as heightened
angiotensin II is thought to promote vasoconstriction, proteinuria,
cellular adhesion, proliferation, and hypertrophy as well as extra-
cellular matrix dysregulation [9–11]. Many of these same processes that
contribute to atherosclerosis have been linked to angiotensin II actions
[12,13]. Although the cardioprotective effects of RAAS blockades are
well established in randomized controlled trials on the general popu-
lation [14–16], their effects on clinical endpoints in CKD patients re-
main uncertain [16]. According to a meta-analysis to examine the effect
of RAAS blockades on CV outcomes in CKD, RAAS blockades were not
associated with a statistically significant reduction in the risk of fatal
and nonfatal CV events [17,18]. These studies suggested that uremic
toxins may play a pivotal role in interfering with the protective effects
of RAAS blockades in CKD.
Endothelial dysfunction has been considered the key step in the
pathogenesis of atherosclerosis [19]. Endothelium-derived NO is a cri-
tical regulator of the physiological functions of endothelial cells. The
production of NO in endothelial cells is generated mainly via the acti-
vation of endothelial nitric oxide synthase (eNOS) [20]. Deregulation of
eNOS activity is a key event in the development of CVDs, such as
atherosclerosis and hypertension [21,22]. Our previous study demon-
strated that valsartan, an antagonist of the selective angiotensin II type
1 receptor (AT1R), rapidly induces the phosphorylation of eNOS at
Ser1179 and not at Thr495, accompanied by dissociation of eNOS and
AT1R, which consequently increases NO production via the Src/PI3K/
Akt dependent mechanism [23]. Until now, the direct cross-link
Fig. 1. IS impairs NO generation and attenuates valsartan-mediated NO production and tube formation in HAECs. (A) HAECs were treated with IS (0, 15, 30,
60, 120, 240 μg/mL) for 18 h. (B) HAECs were treated with 240 μg/mL IS for the indicated times (0, 3, 6, 9, 12, 18 h). The level of nitrite in the culture medium was
measured by the Griess assay. (C) HAECs were pretreated with IS (15, 30, 60, 120, 240 μg/mL) for 1 h and then with valsartan (10 μM) for 18 h. (D) HAEC
proliferation or (E) migration was determined by BrdU incorporation assay or wound healing migration assay, respectively. (F) HAECs were cultured in precoated
ECL Cell Attachment Matrix with the indicated treatment agents. Tube formation was visualized; the bar graphs indicate the fold of branch points in 5 randomly
selected microscopy views. (G–J) HAECs were pretreated with indicated concentrations of IS for 1 h in the presence of human serum albumin (4 g/dL) and then with
valsartan (10 μM) for 18 h. (G) Nitrite level in the culture medium, (H) proliferation, (I) migration, and (J) tube formation were determined. Values are presented as
the mean ± SEM of 5 separate experiments. *P < 0.05 vs. vehicle-treated cells, #P < 0.05 vs. valsartan-treated cells.
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between IS and ARB signaling in eNOS activity and CV tissues has never
been reported. Since severe endothelial dysfunction is frequently ob-
served in CKD [24,25], it is reasonable to postulate that uremic toxins
not only direct injury to the endothelium but also interfere with the
cardioprotective effect of ARB in CKD.
Therefore, first, we conducted an in vitro assay to investigate NO
production and various phosphorylation sites and possible signaling
cascades in IS and/or valsartan-treated human aortic endothelial cells
(HAECs). Second, to confirm our in vitro findings, we carried out the
Matrigel plug assay to assess the effect of IS on valsartan-elicited an-
giogenesis in vivo. Finally, to mimic the clinical situation in CKD, we
explored the effect of IS on valsartan-induced neovascularization and
possible mechanisms in subtotal nephrectomy (SNx) mice after hin-
dlimb ischemia (HI) surgery.
2. Materials and methods
A detailed description of the methods can be found in the
Supplemental Material.
2.1. In vitro studies
HAECs (Cascade Biologics, Portland, OR, USA) were treated with IS,
valsartan, calphostin C, or apocynin. Nitrite was measured by Griess
reagent [23]. The membrane-permeable probe hydroethidine (HE) and
2′,7′-dichlorofluorescin diacetate (DCFH-DA) (Molecular Probes, Eu-
gene OR, USA) were used to assess intracellular ROS levels [26]. The
activity of NADPH oxidase was analyzed using an EnzyChrom™
NADP+/NADPH assay kit [26]. Western blot analysis was performed as
described [23]. The cell proliferation, migration and tube formation
assay were performed to evaluate endothelial function as previously
described [27].
2.2. In vivo studies
The Matrigel plug angiogenesis assay was used to evaluate the
formation of new blood vessels in vivo as previously described [28]. SNx
was induced in 8-week-old male C57BL/6 mice using a 2-step surgical
nephrectomy as previously described [27,29]. Five weeks after SNx,
hindlimb ischemic surgery was performed on all SNx mice. For SNx, a
fluorescence-activated cell sorting (FACS) Caliber flow cytometer
(Becton Dickinson, San Jose, CA, USA) was used to assess EPC mobi-
lization [28]. The blood flow ratio of the ischemic limb (right)/non-
ischemic limb (left) was measured with a laser Doppler perfusion im-
ager system (Moor Instruments Limited, Devon, UK) [28].
2.3. Statistical analysis
The experiments were repeated five times and three replicates were
performed in each cell culture experiments. The results are expressed as
the mean ± SEM. The Mann-Whitney U test was used to compare 2
independent groups. The Kruskal-Wallis test followed by Bonferroni
post hoc analysis was used for multiple testing. Differences were con-
sidered statistically significant when P < 0.05.
3. Results
3.1. IS attenuates NO production and further inhibits valsartan-induced NO
production and tube formation in HAECs
To explore whether IS is capable of inhibiting NO production in
HAECs, HAECs were treated with various concentrations of IS or at
indicated times, and nitrite levels were assessed. We first found that IS
significantly suppressed the nitrite level in a dose-dependent manner at
IS concentrations of 60–240 μg/mL (Fig. 1A). IS concentrations of
60–240 μg/mL fall within a higher but clinically achievable range of
plasma IS concentrations in dialysis patients [29]. In addition, HAECs
were treated with 240 μg/mL for 0, 3, 6, 9, 12, or 18 h. We also found
that IS decreased the nitrite levels in a time-dependent manner at 9, 12,
and 18 h (Fig. 1B). Our previous study demonstrated that valsartan
induced NO production and tube formation in endothelial cells [23].
The effects of IS on valsartan-mediated NO production and tube for-
mation were further examined. HAECs were pretreated with IS con-
centrations of 15, 30, 60, 120, or 240 μg/mL for 1 h and then with
Fig. 2. Effects of IS on eNOS phosphorylation at various sites in HAECs. HAECs were treated with IS (240 μg/mL) for the indicated times (0, 0.5, 1, 2, 4, 8, 12,
18 h). (A–E) Cellular lysates were subjected to Western blot analysis to evaluate the phosphorylation of eNOS at Thr495, Ser615, Ser633, Ser1177 or eNOS. Data are
expressed as the mean ± SEM. *P < 0.05 vs. vehicle-treated cells.
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valsartan at 10 μM for 18 h. Valsartan significantly increased the nitrite
level in HAECs in the absence of human serum albumin (Fig. 1C).
Furthermore, IS at concentrations of 60–240 μg/mL significantly de-
creased nitrite production in HAECs in a dose-dependent manner
(Fig. 1C). Similarly, valsartan significantly increased proliferation and
migration and improved tube formation in HAECs (Fig. 1D–F). Pre-
treatment with IS (240 μg/mL) markedly impaired valsartan-induced
proliferation and migration and tube formation (Fig. 1D–F). Similarly,
IS exhibited a similar inhibitory effect on valsartan-induced NO pro-
duction, EC proliferation, migration and tube formation in the presence
of human serum albumin (4 g/dL) in culture medium (Fig. 1G–J).
3.2. IS increases the phosphorylation of eNOS at Thr495 in HAECs
It is well established that the phosphorylation status of eNOS is
critical for the regulation of its activity [27]. Therefore, we assessed the
effects of IS on eNOS phosphorylation at various sites. Treatment with
IS time-dependently increased the phosphorylation of eNOS at Thr495.
However, IS had no effect on the phosphorylation of eNOS at Ser615,
Ser633 or Ser1177. These findings suggest that IS may elicit a negative
regulatory mechanism to reduce the enzymatic activity of eNOS
(Fig. 2).
3.3. IS attenuates valsartan-mediated increase in NO production,
proliferation, migration and tube formation in HAECs via increasing
phosphorylation of protein kinase C
We next explored the molecular mechanism by which IS impairs NO
production. Protein kinase C (PKC) is reportedly the key kinase re-
sponsible for the phosphorylation of eNOS at Thr495 in endothelial
cells [27]. Our results showed that IS time-dependently increased PKCα
phosphorylation at Ser657, which peaked at 3–9 h and then gradually
decreased to the basal level (Fig. 3A). Blocking PKC activation by cal-
phostin C diminished the IS-induced phosphorylation of eNOS at
Thr495 (Fig. 3B). Additionally, the reduction in valsartan-stimulated
NO production, proliferation, migration and tube formation by IS was
reversed by pretreatment with calphostin C (Fig. 3C–H). These findings
indicate the essential role of the PKC signaling pathway in the in-
hibitory effects of IS on valsartan-mediated endothelial functions.
3.4. The NADPH oxidase-ROS pathway is required for the detrimental
effects of IS on valsartan-mediated endothelial functions
Our data demonstrated that treatment with IS time-dependently
increased ROS production and NADPH oxidase activity (Fig. 4A–C).
Moreover, the inhibition of NADPH oxidase by apocynin abolished the
detrimental effects of IS on ROS production, the phosphorylation of
Fig. 3. Effect of IS on PKC phosphorylation, valsartan-mediated NO production and tube formation in HAECs. (A) HAECs were treated with IS (240 μg/mL) for
the indicated times (0, 3, 6, 9, 12, 18 h). (B) Cells were preincubated with the PKC inhibitor calphostin C (1 μM) for 2 h and then with IS (240 μg/mL) for 18 h.
Cellular lysates were subjected to Western blot analysis to evaluate the phosphorylation of PKCαSer657 and eNOSThr495. HAECs were incubated with the indicated
treatment agent and (C) the level of nitrite in the culture medium, (D) proliferation, (E) migration and (F) tube formation were assessed. (G) The representative
images for cell migration. (H) The representative images for tube formation. Data are expressed as the mean ± SEM. *P < 0.05 vs. vehicle-treated cells. #P < 0.05
vs. valsartan-treated cells, &P < 0.05 vs. IS + valsartan-treated cells.
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PKCα and eNOS at Thr495, and the valsartan-mediated NO production
and tube formation (Fig. 4D–G). These results suggest that the NADPH
oxidase-ROS pathway plays an important role in the inhibitory effects
of IS on valsartan-mediated endothelial functions.
3.5. IS limits valsartan-elicited angiogenesis in vivo
To confirm the in vitro findings, we used Matrigel plug assays to
assess the effects of IS on valsartan-elicited angiogenesis in vivo. As
shown in Fig. 5, valsartan promoted vascularization, as determined by
the hemoglobin content, in Matrigel plugs in wild-type mice. Combined
treatment of the Matrigel plugs with IS and valsartan significantly de-
creased the content of hemoglobin compared with that in the group
treated with only valsartan. Moreover, the limitations of IS on angio-
genesis were markedly restored by cotreatment with calphostin C or
apocynin. These findings suggest that the NADPH oxidase-ROS-PKC
signaling pathway plays a pivotal role in the adverse effects of IS-
mediated valsartan inhibition on endothelial function in vivo.
3.6. IS impairs valsartan-mediated blood perfusion in the ischemic limbs of
SNx mice after HI surgery
To mimic the clinical situation in CKD, we explored the effect of IS
on valsartan-induced neovascularization and possible mechanism in
SNx mice after HI surgery. Fig. 6A showed the protocol of the effect of
IS on valsartan-induced neovascularization in SNx mice after HI sur-
gery. The plasma IS and blood pressure levels in each SNx mouse group
were shown in Fig. S1 and Fig. S2, respectively. The plasma IS level was
similar to the current average value of 23.1 μg/mL observed in an
average dialysis population as reported in the most recent review of the
European Uremic Toxin Group [30]. Moreover, valsartan significantly
improved the blood flow reperfusion in the ischemic limbs of the SNx
mice. However, IS impaired the protective effect of valsartan-induced
increase in blood perfusion in ischemic limbs. Cotreatment with
Fig. 4. The NADPH oxidase-ROS pathway plays a crucial role in the harmful effect of IS on valsartan-mediated NO production and tube formation in
HAECs. (A–C) HAECs were treated with IS (240 μg/mL) for the indicated times. The membrane-permeable probe hydroethidine and 2′,7′-dichlorofluorescin diacetate
were used to examine intracellular ROS levels. (D) HAECs were pretreated with or without the NAD(P)H oxidase inhibitor apocynin (150 μM) for 2 h and then with IS
(240 μg/mL) for 60 min. Intracellular ROS levels and NADPH oxidase activities were analyzed by the intensities of the red fluorescent ethidium (ETH) product and
the green fluorescent product dichlorofluorescin (DCF) and the NADP+/NADPH assay kit, respectively. (E) Cells were preincubated with apocynin (150 μM) for 2 h
and then with IS (240 μg/mL) for 9 h or 18 h. Cellular lysates were subjected to Western blot analysis to evaluate the phosphorylation of PKCα and eNOSThr495. Cells
were incubated with the indicated treatment agent and (F) the levels of nitrite in the culture medium and (G) tube formation was assessed. Data are expressed as the
mean ± SEM. *P < 0.05 vs. vehicle-treated cells. #P < 0.05 vs. IS-treated cells, &P < 0.05 vs. IS + valsartan-treated cells.
Fig. 5. IS impairs valsartan-induced angiogenesis in vivo. Eight-week-old male wild-type mice were subcutaneously injected with Matrigel plugs containing the
indicated treatment agents. At 7 days post administration, the plugs were removed and photographed, and the hemoglobin content was analyzed. Data are presented
as the mean ± SD from 10 mice. *P < 0.05 vs. vehicle-treated mice. #P < 0.05 vs. valsartan-treated mice, &P < 0.05 vs. valsartan + IS-treated mice.
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calphostin C or apocynin abrogated the detrimental effect of IS on blood
perfusion induced by valsartan in ischemic limbs (Fig. 6B–D). These
findings were consistent with the abovementioned Matrigel plug assay
results.
3.7. IS limits the valsartan-induced neovascularization in the ischemic limbs
of SNx mice after HI surgery
We further demonstrated that valsartan significantly improved EPC
mobilization in circulation and the density of CD31+ capillaries in the
ischemic limbs of SNx mice (Fig. 7A and B). However, IS diminished the
protective effect of valsartan-induced neovascularization and increased
the expression of p-PKCαSer657 and p-eNOSThr497 in ischemic limbs
(Fig. 7C). Cotreatment of calphostin C or apocynin reversed the IS-
impaired neovascularization induced by valsartan and decreased the
expression of p-PKCαSer657 and p-eNOSThr497 in ischemic limbs (Fig. 7A
and C). These findings suggest that the NADPH oxidase-ROS-PKC sig-
naling pathway may play a pivotal role in the IS-mediated inhibition of
valsartan-conferred beneficial effects on endothelial function in vivo. A
schematic illustration of the proposed mechanistic inhibition of IS on
valsartan-induced neovascularization via NADPH oxidase and the PKC
signaling pathway in SNx mice is shown in Fig. 7D.
4. Discussion
Endothelium-derived NO plays a pivotal role in the physiological
functions of endothelial cells and endothelial progenitor cells
[22,28,31]. NO bioavailability is tightly controlled by the enzymatic
activity of eNOS [32]. Several studies have shown that increasing the
NO bioavailability using pharmacological agents may be a therapeutic
strategy for treating eNOS-related human diseases [23,33,34]. Val-
sartan abolishes the action of angiotensin II on AT1R, which exerts
various antihypertensive effects, including relaxation of vascular
smooth muscle cells (VSMCs) and inhibition of VSMC proliferation
[35,36]. In addition, valsartan possesses pleiotropic activities, in-
cluding antiathergenic, antiinflammatory, antiplatelet aggregation, and
antithrombotic actions [37–39], all of which are linked to the bioa-
vailability of NO. Furthermore, our previous study further disclosed
that valsartan induces phosphorylation of eNOS, accompanied by dis-
sociation of eNOS and AT1R, which consequently increases NO pro-
duction via the Src/PI3K/Akt signaling pathway [23].
Deregulation of eNOS activity is a key event in the development of
hypertension and impaired angiogenesis in ischemic tissue diseases
[40,41]. In addition to transcriptional regulation, posttranslational
modifications are a crucial mechanism for regulating eNOS activity in
response to various stimuli [32,34,41,42]. Among these stimuli, kinase-
dependent phosphorylation at multiple eNOS sites is a pivotal me-
chanism for modulating eNOS activity. Phosphorylation of eNOS at
both Ser1177 and Ser633 in human endothelial cells (Ser1179 and
Ser635 in bovine endothelial cells) by Akt, calmodulin-dependent
protein kinase II and AMP-activated protein kinase increases eNOS
activity [34,42]. In contrast, phosphorylation of eNOS at Thr495 in
human endothelial cells (Thr497 in bovine endothelial cells) by PKC
decreases eNOS activity [34,42]. In our study, we found that IS in-
creased the phosphorylation of eNOS at Thr495 rather than at Ser615,
Ser633 and Ser1177 in HAECs. Moreover, IS attenuated valsartan-
mediated NO production and tube formation in HAECs via increasing
NADPH oxidase and PKCα phosphorylation.
Indole is produced by intestinal bacteria as a degradation product of
the amino acid, tryptophan and is subsequently absorbed and meta-
bolized in the liver to IS, the prototype of protein-bound uremic toxins.
Studies have reported the detrimental effects of IS accumulation, such
as increased ROS production, upregulation of NADPH oxidase, and re-
duced NO bioavailability [5–7]. Several clinical studies support the idea
that IS may contribute to CVD in CKD and end-stage renal disease.
Barreto et al. demonstrated that the serum levels of IS were positively
Fig. 6. Blood perfusion in the ischemic limbs of mice with subtotal nephrectomy after hindlimb ischemic surgery. (A) Protocol illustration of the effect of IS
on neovascularization in SNx mice. Uremia was induced in 8-week-old male C57BL/6 mice using two-step subtotal nephrectomy (SNx). One week after subtotal
nephrectomy, six SNx mouse groups receiving vehicle or medications in the following six weeks were created as follows: mice were administered with vehicle, mice
were administered with valsartan (60 mg/kg/day in drinking water), mice were administered with IS intraperitoneally (IP, 100 mg/kg thrice a week), mice were
administered with IS + valsartan, mice were administered with IS + valsartan + IP calphostin C (10 μg/kg thrice a week), mice were administered with
IS + valsartan + IP apocynin (50 mg/kg thrice a week). (B) Blood perfusion in the ischemic hindlimb was measured before, immediately after, and at 1 and 2 weeks
after hindlimb ischemic (HI) surgery by laser Doppler. (C) Quantification and (D) representative images of blood perfusion in the ischemic hindlimb was measured at
2 weeks after HI surgery by laser Doppler. Data are presented as the mean ± SEM from 8 mice. *P < 0.05 vs. vehicle-treated mice. #P < 0.05 vs. valsartan-treated
mice, &P < 0.05 vs. IS + valsartan-treated mice.
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and significantly associated with aortic calcification and pulse wave
velocity in patients at different stages of CKD [8]. Moreover, the highest
IS tertile was a powerful predictor of overall and cardiovascular mor-
tality [8]. Additionally, Lin et al. determined that the serum IS level was
a valuable marker for predicting CV events in patients with advanced
CKD [43].
Until now, evidence from experimental studies demonstrated that
endothelial dysfunction [7,44–46], smooth muscle cell lesions [47,48],
coagulation disturbances [47], leukocyte activation [45], cross-talk
between leukocytes and the endothelium [45], cardiac fibrosis and
hypertrophy [49], and whole-vessel alterations [50] are all linked to IS
and cardiovascular damage. However, the direct cross-link between IS
and ARB signaling in eNOS activity and further cardiovascular damage
has never been reported. This hypothesis was first validated by our in
vitro experiments (Figs. 1 and 2). We found that IS impaired the val-
sartan-mediated phosphorylation of eNOS at Thr495, NO production
and tube formation in HAECs via NADPH oxidase and PKC phosphor-
ylation, but these effects were suppressed by cotreatment with apocynin
(NADPH oxidase inhibitor) and calphostin C (PKC inhibitor). Moreover,
using in vivo experiments, we also demonstrated that IS attenuated
valsartan-induced angiogenesis in Matrigel plugs in mice. Finally, to
mimic the clinical condition in CKD, we used subtotal nephrectomized
mice to validate the effect of IS on ischemia-mediated neovasculariza-
tion. We demonstrated that valsartan significantly improved the EPC
mobilization in circulation and the reperfusion of blood flow and
density of CD31+ capillaries in the ischemic limbs of CKD mice.
However, IS attenuated the protective effect of valsartan-induced neo-
vascularization and increased the expression of p-PKCαSer657 and p-
eNOSThr497 in the ischemic limbs of CKD mice. Cotreatment with
apocynin and calphostin C reversed the IS impaired-neovascularization
and decreased the expression of p-PKCαSer657 and p-eNOSThr497 in the
ischemic limbs of CKD mice. To our knowledge, this study is the first to
show that IS impairs the protective effect of valsartan-mediated en-
dothelial function in HAECs and neovascularization in CKD mice via the
NADPH oxidase and PKC signaling pathways. We demonstrated that IS
in not only a direct vascular toxin but also plays an important role in
uremic toxin and drug interactions. Our study supports the meta-ana-
lysis study by Tai et al. [18] and that the use of RAAS blockades is not
associated with a statistically significant reduction in the risk of CV
events in CKD patients, unlike in the general population. Our results
also provide another explanation for the high CV risk in CKD patients.
From a clinical viewpoint, several issues merit discussion in this
Fig. 7. IS impairs valsartan-induced neovascularization in the ischemic limbs of SNx mice after HI surgery. (A) Circulating Sca-1+/Flk-1+ cells were analyzed
by flow cytometry at baseline and at 2 days after HI surgery. (B) Representative images and quantification of CD31 positive capillaries in the ischemic muscles. Scale
bar = 50 μm. (C) Verification and quantification of phosphor-PKCαSer657 (p-PKCαSer657), phosphor-eNOSThr497 (p-eNOSThr497), PKCα and eNOS in the ischemic
hindlimbs by Western blot analysis. (D) Schematic illustration of the proposed mechanism by which IS inhibits valsartan-induced neovascularization via the NADPH
oxidase (NOX) and PKC signaling pathways in SNx mice. The results are presented as the means ± SEM. *P< 0.05 vs. vehicle-treated mice. #P< 0.05 vs. valsartan-
treated mice, &P < 0.05 vs. IS + valsartan-treated mice.
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study. First, IS concentrations of 60–240 μg/mL in our in vitro study
were within a higher but clinically achievable range of the plasma IS
concentrations in dialysis patients [29]. Duranton et al. have used the
similar IS concentrations in previous in vitro experiments [30]. Second,
most IS binds to albumin in the blood. The culture medium for HAEC in
our in vitro experiments contained 5% FBS, and the calculated albumin
concentration was approximately 85–170 mg/dl. This concentration
indicates that the medium in in vitro experiments was not albumin-free
and mimicked in vivo conditions. Our data provide insight into the
molecular mechanisms underlying the IS-mediated inhibition of val-
sartan-conferred beneficial effects in normal physiological situations,
and an increase in IS levels may predispose mice to more down-
regulated valsartan-mediated endothelial function and impair the pro-
mising effect of valsartan-mediated neovascularization in CKD. Third,
intriguingly, although IS interfered with eNOS activity in our in vitro
and in vivo studies, the increased IS levels did not further increase the
blood pressures of CKD mice. This finding indicates that the adverse
effect of IS on the cardiovascular system was BP-independent. Finally,
since our study demonstrated that IS can constrain the cardiovascular
protective effect of valsartan in vivo and in vitro, the current and our
previous findings are important to support the increasingly recognized
phenomenon that IS is not merely a cardiovascular toxin but also
functions in toxin-drug interactions. Interventions aimed at preventing
indole absorption and IS production can be achieved by three ap-
proaches, including dietary protein restriction, maintenance of gut
symbiosis, and treatment with Kremezin (Kureha Chemical Industry,
Tokyo, Japan), an oral charcoal adsorbent of uremic toxins [51]. En-
couraging results, both decreased IS levels by treating with Kremezin
and CV protective effects, have been shown in patients with CKD from
some clinical studies [46,52–54].
In conclusion, the results of in vitro experiments demonstrated that
the NADPH oxidase/PKC/eNOS phosphorylation signaling pathway
plays a pivotal role in the IS-mediated inhibition of valsartan-conferred
beneficial effects on endothelial function. In addition, IS limited the
valsartan-elicited angiogenesis in a Matrigel plug assay in mice. Finally,
we also demonstrated that IS attenuated valsartan-mediated neo-
vascularization in SNx mice who underwent hindlimb ischemia. We
herein demonstrate novel mechanisms by which IS detrimentally in-
terferes with the therapeutic efficacy of valsartan in CKD. Likewise, our
results together with those of our previous study [27] provide com-
pelling evidence of potential adverse CV outcomes for CKD patients
with high plasma IS levels. Oral charcoal sorbents may potentially offer
a therapeutic rationale for the prevention and treatment of impaired
neovascularization in CKD patients with cardiovascular disease.
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